Moon Jin Soo
Department of Pediatrics, Seoul National University Children's Hospital, Seoul National University College of Medicine, Seoul, Korea.
Intest Res. 2019 Jan;17(1):17-23. doi: 10.5217/ir.2018.00139. Epub 2019 Jan 9.
The incidence of pediatric inflammatory bowel disease (IBD) is increasing worldwide, especially in the developing countries. It differs from adult disease in clinical manifestations, especially with regard to genetic predisposition in monogenic IBD. Pediatric disease also have a tendency to show more aggressive inflammation and greater extent of lesion. Newer drugs such as antitumor necrosis factor α have been known to make a difference in treating pediatric IBD. Recent studies suggested that the patients with high risk factors might have some benefits from earlier use of biologics. To achieve treatment goals such as relieving symptoms, optimizing growth, and improving quality of life while minimizing drug toxicity, more research is needed to develop tools for risk stratification in the use of biologics for pediatric IBD.
儿童炎症性肠病（IBD）在全球范围内的发病率正在上升，尤其是在发展中国家。它在临床表现上与成人疾病不同，特别是在单基因IBD的遗传易感性方面。儿科疾病还倾向于表现出更具侵袭性的炎症和更大范围的病变。已知诸如抗肿瘤坏死因子α等新型药物在治疗儿童IBD方面会产生效果。最近的研究表明，具有高风险因素的患者可能会从早期使用生物制剂中获益。为了实现缓解症状、优化生长发育以及改善生活质量等治疗目标，同时将药物毒性降至最低，需要开展更多研究来开发用于儿童IBD生物制剂使用风险分层的工具。
